Publicação
Is ready-to-use abobotulinumtoxinA more effective than OnabotulinumtoxinA for glabellar lines? A randomized, controlled, triple-blinded clinical trial
| datacite.subject.fos | Ciências Médicas::Ciências da Saúde | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| dc.contributor.author | Gonçalves, Jacqueline Rosa | |
| dc.contributor.author | Valesan, Ligia Figueiredo | |
| dc.contributor.author | Shishido, Ana Claudia Laureano Navarro | |
| dc.contributor.author | Sanchez-Ayala, Alfonso | |
| dc.contributor.author | Carbone, Ana Claudia | |
| dc.contributor.author | Câmara-Souza, Mariana Barbosa | |
| dc.contributor.author | Canales, Giancarlo De la Torre | |
| dc.date.accessioned | 2026-06-15T08:57:51Z | |
| dc.date.available | 2026-06-15T08:57:51Z | |
| dc.date.issued | 2026-04 | |
| dc.description.abstract | Background: Most commercially available botulinum toxin A (BoNT-A) formulations are lyophilized or vacuum-dried powders requiring reconstitution. Recently a ready-to-use formulation (RTUaboBoNT-A) has been introduced. Although its efficacy in reducing glabellar lines has been reported, comparative data with powder onabotulinumtoxinA (OnaBoNT-A) remain limited. Aims: To evaluate the efficacy, durability, and safety of RTUaboBoNT-A compared with OnaBoNT-A for moderate to severe glabellar wrinkles: Methods: Forty women (25–50 years) were randomly allocated to receive either OnaBoNT-A (n = 20) or RTUaboBoNT-A (n = 20) at equivalent doses in the procerus and corrugator muscles. Outcomes included Electromyography activity (EMG), Merz 5-point glabellar lines scale, FACE-Q satisfaction scores, perceived age and pain intensity (VAS). Assessments were performed at baseline and 1, 2-, 3-, 4- and 5-months post-injection. Statistical analysis included two-way repeated-measures ANOVA with Bonferroni's post hoc, chi-squared tests and independent Student's t-tests. Results: No significant intergroup differences were observed in EMG activity of the assessed muscles across follow-ups (p > 0.05). Glabellar lines severity was comparable between groups at rest and maximum contraction throughout the study (p > 0.05). Higher satisfaction scores were observed at 2-months in the OnaBoNT-A group (p = 0.01). Pain during injection was greater with RTUaboBoNT-A (p = 0.02). No intergroup differences were found in perceived age (p > 0.05). Conclusion: The RTUaboBoNT-A demonstrated similar efficacy, durability, and safety profile to OnaBoNT-A for the treatment of glabellar lines. With minor differences in satisfaction and injection disconfort. | eng |
| dc.identifier.citation | J. R. Gonçalves, L. F. Valesan, A. C. L. N. Shishido, et al., “Is Ready-To-Use AbobotulinumtoxinA More Effective Than OnabotulinumtoxinA for Glabellar Lines? A Randomized, Controlled, Triple-Blinded Clinical Trial,” Journal of Cosmetic Dermatology25, no. 4 (2026): e70816, https://doi.org/10.1111/jocd.70816 | |
| dc.identifier.doi | 10.1111/jocd.70816 | |
| dc.identifier.issn | 1473-2165 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/63575 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Wiley | |
| dc.relation.hasversion | https://doi.org/10.1111/jocd.70816 | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | botulinum toxin type | |
| dc.subject | glabellar lines | |
| dc.subject | onabotulinumtoxinA | |
| dc.subject | ready-to-use abobotulinumtoxinA | |
| dc.title | Is ready-to-use abobotulinumtoxinA more effective than OnabotulinumtoxinA for glabellar lines? A randomized, controlled, triple-blinded clinical trial | eng |
| dc.type | contribution to journal | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 4 | |
| oaire.citation.startPage | e70816 | |
| oaire.citation.title | Journal of Cosmetic Dermatology | |
| oaire.citation.volume | 25 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |